The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

The FDA has approved Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.

For US adult cancer survivors with a new alcohol use disorder diagnosis, the 1-year cumulative incidence of treatment initiation was 14.3%.

Nontraumatic subarachnoid hemorrhage remains one of the most common cardiovascular and neurological causes of death and disabilities in the world.

Both mild and moderate-to-severe psoriasis are significantly associated with an increased risk for sleep disorders.

Patients with acute episodic migraine consistently prioritize pain relief over other treatment attributes such as route of administration, adverse outcomes, and costs, according to study results ...

For adult patients with transient ischemic attack/mild stroke, disturbed sleep is associated with greater cerebral small vessel disease burden and worse cognitive outcomes.

Spinal cord stimulation can reduce pain and restore nerve function among patients with diabetic peripheral neuropathy.

Central hypersomnolence disorders, such as narcolepsy type 2 and idiopathic hypersomnia, are associated with reduced health-related quality of life.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Higher adherence to the MIND diet in mid to late life is associated with a reduced risk for Alzheimer disease and related dementias.

The Food and Drug Administration has granted Fast Track designation to ATH434 for the treatment of multiple system atrophy.